Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | C420R |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA C420R lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C420R confers a gain of function on Pik3ca, as indicated by constitutive phosphorylation of downstream targets Akt and S6, increased cell proliferation and migration, and is transforming in cell culture (PMID: 17376864, PMID: 29533785, PMID: 34779417). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA C420R PIK3CA mutant PIK3CA exon8 PIK3CA C420R |
Transcript | NM_006218.4 |
gDNA | chr3:g.179210192T>C |
cDNA | c.1258T>C |
Protein | p.C420R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713658.5 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA C420R | breast cancer | sensitive | Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, Miransertib (ARQ092) treatment induced cell death and inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R in culture (PMID: 32439931). | 32439931 |
PIK3CA C420R | ovarian clear cell adenocarcinoma | sensitive | DS-7423 | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419). | 24504419 |
PIK3CA C420R | breast cancer | predicted - sensitive | Ipatasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Ipatasertib (GDC-0068) treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R in culture (PMID: 32439931). | 32439931 |
PIK3CA C420R | breast cancer | sensitive | MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, MK2206 treatment induced cell death and inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R in culture (PMID: 32439931). | 32439931 |
PIK3CA C420R | Advanced Solid Tumor | sensitive | Sirolimus | Preclinical | Actionable | In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864). | 17376864 |
PIK3CA C420R | breast cancer | predicted - sensitive | GSK690693 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK690693 treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R in culture (PMID: 32439931). | 32439931 |
PIK3CA C420R | breast cancer | sensitive | ARQ 751 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 751 treatment induced cell death and inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R in culture (PMID: 32439931). | 32439931 |
PIK3CA C420R | Her2-receptor positive breast cancer | sensitive | ZM-PI05 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ZM-PI05 induced cell cycle arrest and decreased viability of an ERBB2 (HER2)-positive breast cancer cell line harboring PIK3CA C420R in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38986734). | 38986734 |